<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01931306</url>
  </required_header>
  <id_info>
    <org_study_id>1200.193</org_study_id>
    <nct_id>NCT01931306</nct_id>
  </id_info>
  <brief_title>Expanded Access Study of Afatinib in Treatment-naive or Chemotherapy Pre-treated Patients With Non-small Cell Lung Cancer (NSCLC)</brief_title>
  <official_title>An Open Label Expanded Access Program of Afatinib (BIBW 2992) in Treatment-naive or Chemotherapy Pre-treated Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Harboring EGFR Mutation(s)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      To provide expanded access and to evaluate the safety, tolerability and efficacy of afatinib&#xD;
      in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring&#xD;
      Epidermal Growth Factor Receptor (EGFR) mutation(s) and have never been treated with an EGFR&#xD;
      tyrosine kinase inhibitor (TKI)&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Approved for marketing</overall_status>
  <study_type>Expanded Access</study_type>
  <has_expanded_access>No</has_expanded_access>
  <expanded_access_info>
    <expanded_access_type_treatment>Yes</expanded_access_type_treatment>
  </expanded_access_info>
  <condition>Carcinoma, Non-Small-Cell Lung</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Afatinib</intervention_name>
    <description>BIBW2992 low to medium dose once daily</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          1. locally advanced or metastatic Non-Small Cell Lung Cancer&#xD;
&#xD;
          2. Epidermal Growth Factor Receptor mutation positive result per the institution's&#xD;
             testing methodology. Any type of EGFR mutation allowed&#xD;
&#xD;
          3. Treatment na√Øve or patients who have received one line of chemotherapy, chemotherapy&#xD;
             include neo adjuvant and adjuvant chemotherapy within 1 year from enrolment&#xD;
&#xD;
          4. male or female patients age more than 18 years&#xD;
&#xD;
          5. Adequate organ function, defined as all of the following:&#xD;
&#xD;
               1. Absolute Neutrophil Count over 1500 per mm3. ANC over 1000 per mm3 may be&#xD;
                  considered in special circumstances such as benign cyclical neutropenia as judged&#xD;
                  by the investigator and in discussion with the sponsor.&#xD;
&#xD;
               2. Platelet count more than 75,000 per mm3&#xD;
&#xD;
               3. Serum creatinine below 1.5 times of the upper limit of normal&#xD;
&#xD;
               4. Total Bilirubin below 1.5 times upper limit of institutional normal. Patients&#xD;
                  with Gilbert's syndrome total bilirubin must be below 4 times institutional upper&#xD;
                  limit of normal.&#xD;
&#xD;
               5. Aspartate Amino Transferase or Alanine Amino Transferase below three times the&#xD;
                  upper limit of normal, if related to liver metastases below five times ULN.&#xD;
&#xD;
          6. ECOG score between 0 - 2&#xD;
&#xD;
          7. written informed consent by patient or guardian prior to admission into the trial that&#xD;
             is consistent with International Conference on Harmonisation - Good Clinical Practice&#xD;
             guidelines and local law.&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          1. prior treatment with an EGFR tyrosine kinase inhibitor&#xD;
&#xD;
          2. hormonal anti-cancer treatment within 2 weeks prior to start of trial treatment&#xD;
             ,continued use of anti androgens and or gonadorelin analogues for treatment of&#xD;
             prostate cancer permitted&#xD;
&#xD;
          3. radiotherapy within 14 days prior to drug administration, except as follows:&#xD;
&#xD;
               1. Palliative radiation to organs other than chest may be allowed up to 2 weeks&#xD;
                  prior to drug administration, and&#xD;
&#xD;
               2. Single dose palliative treatment for symptomatic metastasis outside above&#xD;
                  allowance to be discussed with sponsor prior to enrolling.&#xD;
&#xD;
          4. major surgery within 4 weeks before starting trial treatment or scheduled for surgery&#xD;
             during the projected course of the trial&#xD;
&#xD;
          5. known hypersensitivity to afatinib or any of its excipients&#xD;
&#xD;
          6. history or presence of clinically relevant cardiovascular abnormalities such as&#xD;
             uncontrolled hypertension, congestive heart failure New York Heart Association&#xD;
             classification of over 3, unstable angina or poorly controlled arrhythmia as&#xD;
             determined by the investigator. Myocardial infarction within 6 months prior to&#xD;
             starting trial treatment.&#xD;
&#xD;
          7. Women of Child-Bearing Potential and men who are able to father a child, unwilling to&#xD;
             use adequate contraception prior to trial entry, for the duration of trial&#xD;
             participation and for at least 2 weeks after treatment has ended.&#xD;
&#xD;
          8. childbearing potential who:&#xD;
&#xD;
               1. are nursing or&#xD;
&#xD;
               2. are pregnant or&#xD;
&#xD;
               3. are not using an acceptable method of birth control, or do not plan to continue&#xD;
                  using this method throughout the trial and,or do not agree to submit to pregnancy&#xD;
                  testing required by this protocol&#xD;
&#xD;
          9. any history of or concomitant condition that, in the opinion of the investigator,&#xD;
             would compromise the patient's ability to comply with the trial or interfere with the&#xD;
             evaluation of safety for the trial drug&#xD;
&#xD;
         10. previous or concomitant malignancies at other sites, except effectively treated&#xD;
             non-melanoma skin cancers, carcinoma in situ of the cervix, ductal carcinoma in situ&#xD;
             or effectively treated malignancy that has been in remission for more than 3 years and&#xD;
             is considered to be cured.&#xD;
&#xD;
         11. requiring treatment with any of the prohibited concomitant medications that can not be&#xD;
             stopped for the duration of trial participation&#xD;
&#xD;
         12. known pre-existing interstitial lung disease&#xD;
&#xD;
         13. presence of poorly controlled gastrointestinal disorders that could affect the&#xD;
             absorption of the trial drug&#xD;
&#xD;
         14. active hepatitis B infection, active Hepatitis C infection&#xD;
&#xD;
         15. meningeal carcinomatosis&#xD;
&#xD;
         16. symptomatic brain metastases, patients with asymptomatic brain metastases, who were&#xD;
             previously treated, are eligible provided they have had Stable Disease for at least 4&#xD;
             weeks on stable doses of medication&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Catholic University of Korea, Bucheon St.Mary's Hospital</name>
      <address>
        <city>Bucheon</city>
        <zip>14647</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gachon University Gil Medical Center</name>
      <address>
        <city>Incheon</city>
        <zip>405-760</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chonnam National University Hwasun Hospital</name>
      <address>
        <city>Jeonnam</city>
        <zip>519-763</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gyeongsang National University Hospital</name>
      <address>
        <city>Jinju</city>
        <zip>660-702</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Catholic University of Korea, Seoul St.Mary's Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>06591</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Severance Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>120-752</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>135-710</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SMG-SNU Boramae Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>156-707</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>November 2018</verification_date>
  <study_first_submitted>August 20, 2013</study_first_submitted>
  <study_first_submitted_qc>August 26, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 29, 2013</study_first_posted>
  <last_update_submitted>November 12, 2018</last_update_submitted>
  <last_update_submitted_qc>November 12, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">November 14, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Afatinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

